Medifast INC 10-Q quarterly reports

Medifast, Inc. announced a substantial decline in revenue and a widening net loss for the second quarter of 2026, primarily driven by a significant decrease in active coaches.

Medifast, Inc. reported a significant revenue decrease for the first quarter of 2026, primarily due to a decline in active earning coaches and the ongoing impact of GLP-1 medications.

Medifast reported a significant revenue decline and net loss in Q3 2025, driven by a substantial decrease in active earning OPTA VIA coaches and ongoing market challenges.

Medifast, Inc. reported a significant 37.4% revenue decrease in Q2 2025, driven by a sharp decline in active OPTA VIA coaches, despite returning to net income.

Medifast's Q1 2025 revenue declined significantly due to a decrease in active earning OPTA VIA coaches, reflecting challenges in customer acquisition amid the rising popularity of GLP-1 medications.

Medifast, Inc. experienced a substantial decrease in revenue and profitability in the third quarter of 2024, primarily due to a decline in active coaches and the impact of GLP-1 medications on the weight loss market.

Medifast's Q2 2024 results show a significant revenue decrease compared to the previous year, as the company navigates a changing market and implements a strategic transformation.

Medifast's revenue plummeted by 49.9% in the first quarter of 2024 as the company faced headwinds from declining coach numbers and increased competition from GLP-1 weight loss medications.